Trials / Recruiting
RecruitingNCT05468905
China Longitudinal Aging and Cognitive Impairment Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,000 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 40 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.
Detailed description
As the population ages in China, the number of patients with neurocognitive disorders such as Alzheimer's disease (AD) and vascular cognitive impairment (VCI) is steadily increasing. The burden of cognitive impairment in China has been an important public health problem. Cohort study on aging and cognitive impairment is urgent to better understand and address this issue. Early prevention, diagnosis and treatment are critical for reduction the burden of cognitive impairment. In this prospective study, subjects will be recruited into one of the five groups based on inclusion and exclusion criteria: 1) CN, 2) MCI 3) AD and 4) VCI. Each of the subjects will be followed up at designated time points up to 5 years. Epidemiological data, medical, imaging (MRI and PET scans), genetic information and various biological samples will be collected during the baseline and follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | None of intervention | None of intervention |
Timeline
- Start date
- 2021-01-10
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2022-07-21
- Last updated
- 2022-07-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05468905. Inclusion in this directory is not an endorsement.